Bernard Christophe BARLAAM,Kurt Gordon PIKE,Janet HAWKINS,Christopher DE SAVI,Melissa Marie VASBINDER,Alexander HIRD,Michelle LAMB
申请号：
MX2017016244
公开号：
MX2017016244A
申请日:
2016.06.27
申请国别(地区):
MX
年份:
2018
代理人:
摘要：
Provided are a series of novel pyridine or pyrimidine derivatives of Formula (I) which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative diseases such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer. A is C(R5) or N； R5 is H, C1-3alkyl, CN or halogen； R2 is optionally substituted 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl； R4 is (A) or (B) wherein X and Y together with the atoms to which they are attached form an optionally substituted, saturated or partially saturated 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S； J is N or CR11； and R11 is H or C1-3alkyl.Se provee una serie de derivados novedosos de piridina o pirimidina que inhiben CDK9 y pueden se útiles para el tratamiento de enfermedades hiperproliferativas. En particular, los compuestos son útiles en el tratamiento de enfermedades proliferativas como por ejemplo cáncer, incluyendo trastornos hematológicos malignos, como por ejemplo leucemia mieloide aguda, mieloma múltiple, leucemia linfocítica crónica, linfoma difuso de células B grandes, linfoma de Burkitt, linfoma folicular y tumores sólidos como por ejemplo cáncer de mama, cáncer de pulmón, neuroblastoma y cáncer de colon.
